We are live on ! Find out more
ANIK icon

Anika Therapeutics

146 hedge funds and large institutions have $336M invested in Anika Therapeutics in 2013 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

389% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 9

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

70% more capital invested

Capital invested by funds: $197M → $336M (+$139M)

45% more call options, than puts

Call options by funds: $3.6M | Put options by funds: $2.48M

32% more funds holding

Funds holding: 111146 (+35)

14% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 42

Holders
146
Holders Change
+35
Holders Change %
+31.53%
% of All Funds
4.22%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
44
Increased
48
Reduced
42
Closed
9
Calls
$3.6M
Puts
$2.48M
Net Calls
+$1.12M
Net Calls Change
-$2.6M

ANIK Hedge Fund Activity: Q4 2013 in Review

146 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2013, worth a combined $336M — up 70% from $197M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new ANIK positions and 9 closed out — a net gain of 35 holders — while 48 added to existing stakes and 42 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $9.87M. The largest seller was TFS Capital, cutting an estimated $5.42M.

  • 146 institutional investors held Anika Therapeutics (ANIK) as of Q4 2013, up from 111 in Q3 2013.
  • Funds reported $336M of Anika Therapeutics stock for Q4 2013, up 70% quarter-over-quarter.
  • 44 funds opened new Anika Therapeutics positions in Q4 2013 and 9 closed out, a net change of +35 holders.
  • The largest Anika Therapeutics buyer in Q4 2013 was BlackRock Fund Advisors, an estimated $9.87M added.
  • The largest Anika Therapeutics seller in Q4 2013 was TFS Capital, an estimated $5.42M sold.

Based on aggregated 13F filings for Q4 2013.